MTNB
Matinas Biopharma Holdings
$0.33
+$0.09 (+37.76%)Jul 27, 2026
Key metrics
The numbers that frame MTNB today
- Market cap
- $2.13M
- P/E (TTM)
- -0.2
- EV / FCF
- -0.1
- ROIC
- -259%
- Div yield
- 0%
- Debt / equity
- 0.4
- 52wk Low
- $0.23
- 52wk High
- $3.09
Growth
Revenue and earnings trend for MTNB
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about MTNB
Is Matinas Biopharma Holdings a good buy?
No. Matinas Biopharma Holdings has poor quality and poor momentum. Both signals point to a weaker setup. Growth looks poor. That could put pressure on the long-term business case. We think Matinas Biopharma Holdings is selling at a very high price.
What is the market capitalization of MTNB?
Matinas Biopharma Holdings's market capitalization is $2.13M.
What is the P/E ratio for MTNB stock?
Matinas Biopharma Holdings's current P/E ratio is -0.2.
What is the 52-week high for MTNB stock?
The 52-week high for Matinas Biopharma Holdings is $3.09. The current close of $0.33 is 89.3% below that high.
What is the 52-week low for MTNB stock?
The 52-week low for Matinas Biopharma Holdings is $0.23. The current close of $0.33 is 43.7% above that low.
Does MTNB stock pay dividends?
Matinas Biopharma Holdings does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for MTNB?
Matinas Biopharma Holdings's Debt / Equity ratio is 0.39.